Long-term pneumococcal vaccine immunogenicity following allogeneic hematopoietic stem cell transplantation.

Langedijk, Annefleur C; van Aalst, Mariëlle; Meek, Bob; van Leeuwen, Ester M M; Zeerleder, Sacha; Meijer, Ellen; Hazenberg, Mette D; Grobusch, Martin P; Goorhuis, Abraham (2019). Long-term pneumococcal vaccine immunogenicity following allogeneic hematopoietic stem cell transplantation. Vaccine, 37(3), pp. 510-515. Elsevier 10.1016/j.vaccine.2018.11.053

[img] Text
1-s2.0-S0264410X18315780-main.pdf - Published Version
Restricted to registered users only
Available under License Publisher holds Copyright.

Download (386kB) | Request a copy

Infection with Streptococcus pneumoniae is a life-threatening, but vaccine preventable complication in patients with allogeneic hematopoietic stem cell transplantation (allo-HSCT). The international consensus on post allo-HSCT immunization schedules, starting 3-6 months after HSCT, focuses on short-term immunogenicity while long-term immunogenicity is not well characterized. The current Dutch immunization schedule, which starts at 12 months post allo-HSCT, was developed as a result of concerns on the coverage of long-term immunogenicity in international guidelines. We recently encountered two cases of allo-HSCT recipients who developed invasive pneumococcal disease (IPD) despite adequate revaccinations, which led us to question the immunogenicity of pneumococcal vaccinations in this patient group, and whether the currently existing vaccination schedules are appropriate. We included allo-HSCT recipients, vaccinated from one year after transplantation, and tested antibody responses to pneumococcal vaccination. We also performed a systematic review. Antibody concentrations were measured in 42 of 103 (41%) patients, with a response rate of 85% to PCV13 and 62% to PPSV23-unique serotypes. In six relevant studies, protection rates varied between 64 and 98%. Antibody responses in early and late vaccination schedules were similar, but adequate antibody responses were maintained better after late vaccination. Therefore, we propose a vaccination schedule that combines the advantages of early and late vaccination. This new schedule has been introduced since March 2018 in the two academic hospitals in Amsterdam, The Netherlands.

Item Type:

Journal Article (Original Article)

Division/Institute:

04 Faculty of Medicine > Department of Haematology, Oncology, Infectious Diseases, Laboratory Medicine and Hospital Pharmacy (DOLS) > Clinic of Haematology and Central Haematological Laboratory

UniBE Contributor:

Zeerleder, Sacha Sergio

Subjects:

600 Technology > 610 Medicine & health

ISSN:

0264-410X

Publisher:

Elsevier

Language:

English

Submitter:

Pierrette Durand Lüthi

Date Deposited:

08 Jan 2019 13:36

Last Modified:

25 Oct 2019 02:04

Publisher DOI:

10.1016/j.vaccine.2018.11.053

PubMed ID:

30502071

Uncontrolled Keywords:

Allogeneic Hematopoietic stem cell transplantation Invasive pneumococcal disease PCV13 PPSV23 Pneumococcal vaccination

BORIS DOI:

10.7892/boris.123269

URI:

https://boris.unibe.ch/id/eprint/123269

Actions (login required)

Edit item Edit item
Provide Feedback